An agent that may fulfill these requirements is the glycan-binding protein Galectin-9 (Gal-9). Indeed, treatment with Gal-9 reduced total cell counts and cell viability of various B cell NHL cell ...

In the autumn of 2022, Freddie Cole was diagnosed with stage 4 Burkitts lymphoma, a rare cancer of both the bone marrow and ...

Burkitt's lymphoma. HIV-related Burkitt's lymphoma (BL) should be managed with intensive therapy such as cyclophosphamide, doxorubicin, vincristine, high-dose methotrexate, ifosphamide, etoposide ...

CHICAGO — In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 WaveLINE-003 trial of patients with relapsed/refractory diffuse B-cell lymphoma ...

CHICAGO — In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor ...

Incyte said it received approval from the Food and Drug Administration for monjuvi, in combination with rituximab and lenalidomide, as a treatment for follicular lymphoma. The biopharmaceutical ...

B-cell lymphoma study identifies traits tied to greatest benefit from CD19 CAR T cell therapy. by Jade Waddy, University of Texas M. D. Anderson Cancer Center ...

Tafasitamab-cxix (Monjuvi) is now FDA-approved with lenalidomide (Revlimid) and rituximab (Rituxan) for adults with relapsed/refractory follicular lymphoma (R/R FL). The inMIND trial (NCT04680052) ...

Aubrey Barnett was 17 when diagnosed with a rare cancer, but says she "tried not to let the cancer treatments stop me" — and was even crowned Homecoming Queen ...